Trial Profile
Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 24 Sep 2015 New trial record